Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
AV-GBM-1
BIOLOGICAL
2 trials
Sponsors
Aivita Biomedical, Inc.
Conditions
Newly Diagnosed Glioblastoma
Primary Glioblastoma
Phase 2
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma
NCT03400917
Aivita Biomedical, Inc.
Newly Diagnosed Glioblastoma
Start: 2018-06-20
End: 2023-02-28
Target: 55
Updated: 2021-12-16
Phase 3
AV-GBM-1 vs Control as Adjunctive Therapy Following Surgery and RT/TMZ in Newly Diagnosed GBM
Not yet recruiting
NCT05100641
Aivita Biomedical, Inc.
Primary Glioblastoma
Start: 2024-01-31
End: 2029-03-31
Target: 672
Updated: 2023-04-10
Related Papers
Fragment Autoantigens Stimulated T‐Cell‐Immunotherapy (FAST) as a Fast Autologous Cancer Vaccine
Advanced Science
2025-03-26
2 citations
1411 Feasibility, safety, and efficacy of personal vaccines consisting of autologous dendritic cells loaded <i>ex vivo</i> with autologous tumor antigens from self-renewing cancer cells
Regular and Young Investigator Award Abstracts
2023-10-31
Final results of phase 2 trial of personal dendritic cell (DC) vaccines loaded with autologous tumor antigens (ATA) in newly diagnosed glioblastoma (GBM).
Journal of Clinical Oncology
2023-06-01
3 citations
Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment.
2022-12-14
40 citations
CTIM-33. PHASE II TRIAL OF VACCINE IMMUNOTHERAPY IN PRIMARY GLIOBLASTOMA: ADJUNCTIVE AUTOLOGOUS DENDRITIC CELLS PULSED WITH LYSATE FROM IRRADIATED SELF-RENEWING AUTOLOGOUS TUMOR CELLS (AV-GBM-1)
Neuro-Oncology
2021-11-02
1 citations
952 Phase II trial of AV-GBM-1: dendritic cell vaccine pulsed with lysate enriched for autologous tumor-initiating cell antigens in the treatment of patients with newly diagnosed glioblastoma
2021-11-01
3 citations
336 Adverse events in a phase II trial of AV-GBM-1: dendritic cell vaccine pulsed with lysate enriched for autologous tumor-initiating cell antigens for patients with newly diagnosed glioblastoma
Regular and Young Investigator Award Abstracts
2021-11-01
331 Tumor markers associated with increased survival in a phase II trial of dendritic cell/tumor-initiating-cell vaccine AV-GBM-1 in patients with newly diagnosed glioblastoma
Regular and Young Investigator Award Abstracts
2021-11-01
335 Leukaphereses to obtain monocytes to produce dendritic cells in manufacturing of personal autologous AV-GBM-1 vaccines in a phase II trial in patients with newly diagnosed glioblastoma
Regular and Young Investigator Award Abstracts
2021-11-01
332 Tumor collection and establishment of tumor-initiating cell cultures as antigen source for AV-GBM-1 dendritic cell vaccines for a phase II trial in patients with newly diagnosed glioblastoma
Regular and Young Investigator Award Abstracts
2021-11-01
333 Changes in proteomic markers after injections of personal AV-GBM-1 dendritic cell/tumor initiating cell vaccines in a phase II trial in patients with newly diagnosed glioblastoma
Regular and Young Investigator Award Abstracts
2021-11-01
319 Phase II trial of immunotherapy in primary glioblastoma: antigens from self-renewing autologous tumor cells presented by autologous dendritic cell vaccine
Regular and Young Investigator Award Abstracts
2020-11-01
CTIM-26. PATIENT-SPECIFIC DENDRITIC CELL VACCINE (DC-ATA) PULSED WITH ANTIGENS FROM SELF-RENEWING AUTOLOGOUS TUMOR CELLS IN THE TREATMENT OF NEWLY-DIAGNOSED GLIOBLASTOMA: A PHASE II TRIAL
Neuro-Oncology
2020-11-01
Abstract CT182: Adjunctive treatment of primary glioblastoma with patient-specific dendritic cell vaccines pulsed with antigens from self-renewing autologous tumor cells: A phase II trial
Cancer Research
2020-08-15